Vivus Muse impotency campaign to raise public awareness following January launch.
Executive Summary
VIVUS MUSE IMPOTENCE PUBLIC AWARENESS CAMPAIGN WILL ACCOMPANY LAUNCH of product in January. The campaign will be directed at physicians and consumers. The company's marketing campaign will also focus on the 8,000 urologists in the U.S., Vivus said. Muse (alprostadil) urethral suppository was approved on Nov. 19 for treatment of erectile dysfunction following an eight-month review; NDA 20-700 for Muse was submitted on March 27.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth